Abstract | BACKGROUND: METHODS: RESULTS: Monotherapy with TAD or AMB led to modest reductions in pulmonary arterial pressure (PAP) and right ventricular (RV) hypertrophy. In contrast, echocardiography and invasive hemodynamic measurements revealed that combined TAD/AMB nearly completely reversed pulmonary hemodynamic impairment, RV hypertrophy, and RV functional deficit in SU-Hx rats. Efficacy of TAD/AMB was associated with dramatic reductions in pulmonary vascular remodeling, including suppression of endothelial cell plexiform lesions, which are common in human PAH. CONCLUSIONS: Combined therapy with two vasodilators that are approved for the treatment of human PAH provides unprecedented efficacy in the rat SU-Hx preclinical model of severe, angioproliferative PAH.
|
Authors | Maria A Cavasin, Kimberly M Demos-Davies, Katherine B Schuetze, Weston W Blakeslee, Matthew S Stratton, Rubin M Tuder, Timothy A McKinsey |
Journal | Journal of translational medicine
(J Transl Med)
Vol. 12
Pg. 314
(Nov 26 2014)
ISSN: 1479-5876 [Electronic] England |
PMID | 25425003
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Phosphodiesterase 5 Inhibitors
- Receptors, Endothelin
|
Topics |
- Animals
- Hypertension, Pulmonary
(therapy)
- Hypertrophy, Right Ventricular
(therapy)
- Male
- Phosphodiesterase 5 Inhibitors
(therapeutic use)
- Rats
- Rats, Sprague-Dawley
- Receptors, Endothelin
(drug effects)
|